Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma

• Published in: Journal of clinical medicine Vol. 11; no. 9; p. 2356
• Main Authors: Beetz, Nick Lasse, Geisel, Dominik, Maier, Christoph, Auer, Timo Alexander, Shnayien, Seyd, Malinka, Thomas, Neumann, Christopher Claudius Maximilian, Pelzer, Uwe, Fehrenbach, Uli
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.04.2022; MDPI
• Subjects: Artificial intelligence; Body composition; Body fat; Body mass index; Cardiovascular disease; Chemotherapy; Clinical medicine; computed tomography; Datasets; Hypotheses; Medical imaging; Medical prognosis; Metabolism; Musculoskeletal system; Obesity; Pancreatic cancer; Patients; Physical fitness; Sarcopenia; Software; Surgery; survival; Tissues; Vertebrae; computed tomography; CT; body composition; pancreatic cancer; survival; AI; artificial intelligence; imaging predictors; oncology; surgery
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11092356

Pancreatic cancer is the seventh leading cause of cancer death in both sexes. The aim of this study is to analyze baseline CT body composition using artificial intelligence to identify possible imaging predictors of survival. We retrospectively included 103 patients. First, the presence of surgical treatment and cut-off values for sarcopenia and obesity served as independent variates. Second, the presence of surgery, subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle index (SMI) served as independent variates. Cox regression analysis was performed for 1-year, 2-year, and 3-year survival. Possible differences between patients undergoing surgical versus nonsurgical treatment were analyzed. Presence of surgery significantly predicted 1-year, 2-year, and 3-year survival (p = 0.01, <0.001, and <0.001, respectively). Across the follow-up periods of 1-year, 2-year, and 3-year survival, the presence of sarcopenia became an equally important predictor of survival (p = 0.25, 0.07, and <0.001, respectively). Additionally, increased VAT predicted 2-year and 3-year survival (p = 0.02 and 0.04, respectively). The impact of sarcopenia on 3-year survival was higher in the surgical treatment group (p = 0.02 and odds ratio = 2.57) compared with the nonsurgical treatment group (p = 0.04 and odds ratio = 1.92). Fittingly, a lower SMI significantly affected 3-year survival only in patients who underwent surgery (p = 0.02). Especially if surgery is performed, AI-derived sarcopenia and reduced muscle mass are unfavorable imaging predictors.